Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
Figure 6
(A) Immunostaining of insulin (red), Ki67 (green), and DAPI (blue) in pancreas sections from non-diabetic control mice and diabetic mice with restored normoglycemia after 7 weeks treatment with PSN632408, sitagliptin, or PSN632408 combined with sitagliptin.
White arrows indicate insulin/Ki67/DAPI co-positive cells. (B) The percentage of insulin/Ki67 co-positive cells among total insulin positive cells was significantly higher in mice treated with PSN632408 and sitagliptin combination than in mice treated with PSN632408 alone or sitagliptin alone (p<0.01, n = 4 to 6 mice per group).